- The Washington Times - Monday, April 16, 2007

ASSOCIATED PRESS

The first dozen Parkinson’s patients to have holes drilled in their skulls for a novel gene therapy attempt weren’t harmed — and hints at some improvement have researchers embarking on a larger study to see whether the treatment really works.

Doctors reported initial results of the closely watched experiment at a neurology meeting yesterday, but cautioned that it’s far too soon to raise hopes.

At issue: Using a nerve growth factor to try to rescue dying brain cells.

Some 1.5 million Americans have Parkinson’s disease, which gradually destroys brain cells that produce dopamine, a chemical crucial for the cellular signaling that controls muscle movement. Too little dopamine causes increasingly severe tremors and periodically stiff or frozen limbs.

Standard treatments can control tremors for a while but can’t stop the disease’s inevitable progression. So scientists are hunting for ways to protect remaining dopamine-producing neurons and rescue dying ones.

Previous attempts with growth factors did not succeed. The new approach uses gene therapy — injecting a virus that carries a gene that in turn produces the growth factor neurturin — to try to get the protective protein right where it’s needed.

None of the first 12 patients to undergo the experiment — at the University of California at San Francisco, and Chicago’s Rush University Hospital — suffered serious side effects, UCSF neurosurgeon Dr. Philip Starr reported yesterday.

A year after treatment, three patients showed no difference on a standard rating scale of movement. But the other nine showed a 38 percent improvement, Dr. Starr told a meeting of the American Association of Neurological Surgeons.

That doesn’t mean the therapy worked, Dr. Starr cautioned. It could have been coincidence; some previous attempts found similar hints of effectiveness, only to fail when put to more rigorous testing.

But the results were encouraging enough that researchers are enrolling more Parkinson’s sufferers — 56 of them — for the next stage of testing. A third of those patients will undergo sham surgery, getting the holes drilled in their skulls but no gene-carrying virus, to try to tease out whether the therapy really works.

California-based Ceregene Inc. sponsored the research.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide